817P - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
Janjigian, Y.Y., Maron, S., Chou, J.F., Gabler, A.R., Simmons, M.Z., Momtaz, P., Shcherba, M., Ku, G.Y., Won, E., Sanchez-Vega, F., Gerdes, H., Kelsen, D.P., Ilson, D.H., Solit, D., Schultz, N., Shah, P.M., Capanu, M., Hechtman, J.F., Lamendola-Essel, M.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
Janjigian, Y.Y., Maron, S., Chou, J.F., Gabler, A.R., Simmons, M.Z., Momtaz, P., Shcherba, M., Ku, G.Y., Won, E., Sanchez-Vega, F., Gerdes, H., Kelsen, D.P., Ilson, D.H., Solit, D., Schultz, N., Shah, P.M., Capanu, M., Hechtman, J.F., Lamendola-Essel, M.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article